NKX2.5 is expressed in papillary thyroid carcinomas and regulates differentiation in thyroid cells

• Published in: BMC cancer 2018-05, Vol.18 (1), p.498-12, Article 498
• Main Authors: Penha, Ricardo Cortez Cardoso, Buexm, Luisa Aguirre, Rodrigues, Fabiana Resende, de Castro, Taciana Padilha, Santos, Maria Carolina S, Fortunato, Rodrigo Soares, Carvalho, Denise P, Cardoso-Weide, Luciene C, Ferreira, Andrea C F
• Format: Article
• Language: English
• Subjects: Adult; Aged; Analysis; Animals; Cancer; Care and treatment; Cell Dedifferentiation - genetics; Cell differentiation; Cell Differentiation - genetics; Cell Line, Tumor; Cell Survival - genetics; Differentiation; Female; Gene Expression; Homeobox Protein Nkx-2.5 - genetics; Homeobox Protein Nkx-2.5 - metabolism; Humans; Immunohistochemistry; Iodide uptake; Male; Middle Aged; NKX2.5; Papillary thyroid carcinoma; Persistence/recurrence; Phenotype; Prognosis; Rats; Reactive Oxygen Species - metabolism; Relapse; Thyroid cancer; Thyroid Cancer, Papillary - genetics; Thyroid Cancer, Papillary - metabolism; Thyroid Gland - metabolism; Transcription factors; Young Adult
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-018-4399-1

NKX2.5 is a transcription factor transiently expressed during thyroid organogenesis. Recently, several works have pointed out the oncogenic role of NKX2.5 in a variety of tumors. We therefore hypothesized that NKX2.5 could also play a role in thyroid cancer. The validation of NKX2.5 expression was assessed by immunohistochemistry analysis in a Brazilian case series of 10 papillary thyroid carcinoma (PTC) patients. Then, the long-term prognostic value of NKX2.5 and its correlation with clinicopathologic features of 51 PTC patients was evaluated in a cohort with 10-years follow-up (1990-1999). Besides, the effect of NKX2.5 overexpression on thyroid differentiation markers and function was also investigated in a non-tumor thyroid cell line (PCCL3). NKX2.5 was shown to be expressed in most PTC samples (8/10, case series; 27/51, cohort). Patients who had tumors expressing NKX2.5 showed lower rates of persistence/recurrence (p = 0.013). Overexpression of NKX2.5 in PCCL3 cells led to: 1) downregulation of thyroid differentiation markers (thyrotropin receptor, thyroperoxidase and sodium-iodide symporter); 2) reduced iodide uptake; 3) increased extracellular H O generation, dual oxidase 1 mRNA levels and activity of DuOx1 promoter. In summary, NKX2.5 is expressed in most PTC samples analyzed and its presence correlates to better prognosis of PTC. In vitro, NKX2.5 overexpression reduces the expression of thyroid differentiation markers and increases ROS production. Thus, our data suggests that NKX2.5 could play a role in thyroid carcinogenesis.